CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled
Drug / intervention
GRF6019 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03765762
NCT03765762Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of Pulsed GRF6019 Infusions in Subjects With Severe Alzheimer's Disease

Alkahest, Inc.·interventional·Posted Dec 5, 2018·Updated Jan 27, 2021

In Brief

A Phase 2 clinical trial evaluating GRF6019 and Placebo for Severe Alzheimer Disease. Completed, enrolled 26 participants across 6 sites.

Detailed Summary

This study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in subjects with severe Alzheimer's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Alzheimer Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedDec 5, 2018
Enrollment StartJan 15, 2019
Primary CompletionDec 17, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.6 years ago

Interventions

GRF6019drug

GRF6019 for IV infusion

Placeboother

Placebo for IV infusion